<?xml version="1.0" ?>
<rss version="2.0">
  <channel>
    <title>ADHD Medications: FAERS Safety Updates</title>
    <link>https://adhd-clearinghouse.com/adhd-faers-updates</link>
    <description>Focused FAERS adverse event monitoring for ADHD medications: Vyvanse, Concerta, Strattera, Ritalin</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Oct 2025 16:55:33 GMT</lastBuildDate>
    <item>
      <title>ADHD Safety Alert: VYVANSE (P) FAERS Profile</title>
      <description>
        &lt;![CDATA[
        &lt;h3&gt;ADHD Medication Safety Profile: VYVANSE (P)&lt;/h3&gt;
        &lt;table border=&quot;1&quot; style=&quot;border-collapse: collapse;&quot;&gt;
        &lt;tr&gt;&lt;th&gt;Metric&lt;/th&gt;&lt;th&gt;Value&lt;/th&gt;&lt;th&gt;Context&lt;/th&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Total Reports&lt;/td&gt;&lt;td&gt;20,950&lt;/td&gt;&lt;td&gt;Lifetime FAERS reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Deaths&lt;/td&gt;&lt;td&gt;44&lt;/td&gt;&lt;td&gt;0.21% of reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Serious Outcomes&lt;/td&gt;&lt;td&gt;3,427&lt;/td&gt;&lt;td&gt;16.36% of reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Active Ingredient&lt;/td&gt;&lt;td&gt;Lisdexamfetamine&lt;/td&gt;&lt;td&gt;Pharmacological class&lt;/td&gt;&lt;/tr&gt;
        &lt;/table&gt;
        &lt;p&gt;&lt;strong&gt;Clinical Context:&lt;/strong&gt; This data should be interpreted alongside prescribing volume, patient population, and reporting patterns.&lt;/p&gt;
        ]]&gt;
        </description>
      <link>https://adhd-clearinghouse.com/medications/lisdexamfetamine</link>
      <guid>adhd-faers-vyvanse-p-20251028</guid>
      <pubDate>Tue, 28 Oct 2025 16:55:33 GMT</pubDate>
    </item>
    <item>
      <title>ADHD Safety Alert: CONCERTA (P) FAERS Profile</title>
      <description>
        &lt;![CDATA[
        &lt;h3&gt;ADHD Medication Safety Profile: CONCERTA (P)&lt;/h3&gt;
        &lt;table border=&quot;1&quot; style=&quot;border-collapse: collapse;&quot;&gt;
        &lt;tr&gt;&lt;th&gt;Metric&lt;/th&gt;&lt;th&gt;Value&lt;/th&gt;&lt;th&gt;Context&lt;/th&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Total Reports&lt;/td&gt;&lt;td&gt;7,605&lt;/td&gt;&lt;td&gt;Lifetime FAERS reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Deaths&lt;/td&gt;&lt;td&gt;61&lt;/td&gt;&lt;td&gt;0.802% of reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Serious Outcomes&lt;/td&gt;&lt;td&gt;1,595&lt;/td&gt;&lt;td&gt;20.97% of reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Active Ingredient&lt;/td&gt;&lt;td&gt;Methylphenidate&lt;/td&gt;&lt;td&gt;Pharmacological class&lt;/td&gt;&lt;/tr&gt;
        &lt;/table&gt;
        &lt;p&gt;&lt;strong&gt;Clinical Context:&lt;/strong&gt; This data should be interpreted alongside prescribing volume, patient population, and reporting patterns.&lt;/p&gt;
        ]]&gt;
        </description>
      <link>https://adhd-clearinghouse.com/medications/methylphenidate</link>
      <guid>adhd-faers-concerta-p-20251028</guid>
      <pubDate>Tue, 28 Oct 2025 16:55:33 GMT</pubDate>
    </item>
    <item>
      <title>ADHD Safety Alert: STRATTERA (P) FAERS Profile</title>
      <description>
        &lt;![CDATA[
        &lt;h3&gt;ADHD Medication Safety Profile: STRATTERA (P)&lt;/h3&gt;
        &lt;table border=&quot;1&quot; style=&quot;border-collapse: collapse;&quot;&gt;
        &lt;tr&gt;&lt;th&gt;Metric&lt;/th&gt;&lt;th&gt;Value&lt;/th&gt;&lt;th&gt;Context&lt;/th&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Total Reports&lt;/td&gt;&lt;td&gt;6,478&lt;/td&gt;&lt;td&gt;Lifetime FAERS reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Deaths&lt;/td&gt;&lt;td&gt;94&lt;/td&gt;&lt;td&gt;1.451% of reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Serious Outcomes&lt;/td&gt;&lt;td&gt;1,694&lt;/td&gt;&lt;td&gt;26.15% of reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Active Ingredient&lt;/td&gt;&lt;td&gt;Atomoxetine&lt;/td&gt;&lt;td&gt;Pharmacological class&lt;/td&gt;&lt;/tr&gt;
        &lt;/table&gt;
        &lt;p&gt;&lt;strong&gt;Clinical Context:&lt;/strong&gt; This data should be interpreted alongside prescribing volume, patient population, and reporting patterns.&lt;/p&gt;
        ]]&gt;
        </description>
      <link>https://adhd-clearinghouse.com/medications/atomoxetine</link>
      <guid>adhd-faers-strattera-p-20251028</guid>
      <pubDate>Tue, 28 Oct 2025 16:55:33 GMT</pubDate>
    </item>
    <item>
      <title>ADHD Safety Alert: RITALIN (P) FAERS Profile</title>
      <description>
        &lt;![CDATA[
        &lt;h3&gt;ADHD Medication Safety Profile: RITALIN (P)&lt;/h3&gt;
        &lt;table border=&quot;1&quot; style=&quot;border-collapse: collapse;&quot;&gt;
        &lt;tr&gt;&lt;th&gt;Metric&lt;/th&gt;&lt;th&gt;Value&lt;/th&gt;&lt;th&gt;Context&lt;/th&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Total Reports&lt;/td&gt;&lt;td&gt;2,735&lt;/td&gt;&lt;td&gt;Lifetime FAERS reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Deaths&lt;/td&gt;&lt;td&gt;23&lt;/td&gt;&lt;td&gt;0.841% of reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Serious Outcomes&lt;/td&gt;&lt;td&gt;605&lt;/td&gt;&lt;td&gt;22.12% of reports&lt;/td&gt;&lt;/tr&gt;
        &lt;tr&gt;&lt;td&gt;Active Ingredient&lt;/td&gt;&lt;td&gt;Methylphenidate&lt;/td&gt;&lt;td&gt;Pharmacological class&lt;/td&gt;&lt;/tr&gt;
        &lt;/table&gt;
        &lt;p&gt;&lt;strong&gt;Clinical Context:&lt;/strong&gt; This data should be interpreted alongside prescribing volume, patient population, and reporting patterns.&lt;/p&gt;
        ]]&gt;
        </description>
      <link>https://adhd-clearinghouse.com/medications/methylphenidate</link>
      <guid>adhd-faers-ritalin-p-20251028</guid>
      <pubDate>Tue, 28 Oct 2025 16:55:33 GMT</pubDate>
    </item>
  </channel>
</rss>
